Please check your internet connection and try again.
# Megacv Duo
*(Note: Megacv Duo typically refers to a fixed-dose combination of Amoxicillin and Clavulanate Potassium (Co-amoxiclav) in varying ratios, often 7:1 or 8:1 depending on the specific product formulation).*
## Overview
Amoxicillin/Clavulanate is a combination penicillin-class antibiotic with a beta-lactamase inhibitor. Amoxicillin provides bactericidal activity against susceptible bacteria, while Clavulanate Potassium inhibits beta-lactamase enzymes, preventing the degradation of amoxicillin.
## Primary Indications
* Community-acquired pneumonia.
* Acute bacterial rhinosinusitis.
* Lower respiratory tract infections.
* Skin and skin structure infections.
* Otitis media (pediatric).
* Urinary tract infections.
## Adult Dosing
Standard dosing is based on the amoxicillin component.
* **Mild to Moderate Infections:** 500 mg/125 mg orally every 8 hours or 875 mg/125 mg orally every 12 hours.
* **Severe Infections/Respiratory Tract Infections:** 875 mg/125 mg orally every 12 hours.
* **Maximum Dose:** Do not exceed 1750 mg of amoxicillin/250 mg of clavulanate daily in divided doses (using the 875/125 mg formulation).
## Pediatric Dosing
Dosing is strictly weight-based and depends on the specific concentration of the suspension used.
* **General Dosing:** 20 mg/kg/day to 45 mg/kg/day (based on amoxicillin component) in divided doses every 8–12 hours.
* **Otitis Media/Recurrent Infections:** Up to 90 mg/kg/day (based on the amoxicillin component) in divided doses every 12 hours, using high-potency formulations (e.g., 600 mg/5 mL).
* *Note:* Ensure the ratio of amoxicillin to clavulanate is appropriate to avoid excessive clavulanate intake, which is associated with diarrhea.
## Dose Adjustments
* **Renal Impairment (CrCl <30 mL/min):** Use is generally not recommended with extended-release tablets or high-dose formulations. Dose reductions and interval extensions are required for standard formulations.
* **Hepatic Impairment:** Use with caution; monitor hepatic function periodically.
## Contraindications
* History of serious hypersensitivity (e.g., anaphylaxis, Stevens-Johnson syndrome) to penicillins or any component of the formulation.
* History of cholestatic jaundice or hepatic dysfunction associated with prior amoxicillin/clavulanate therapy.
## Adverse Effects
* **Common:** Diarrhea, nausea, vomiting, abdominal pain, skin rash, or urticaria.
* **Serious:** Cholestatic jaundice, hepatitis, severe cutaneous adverse reactions (SCARs), Clostridioides difficile-associated diarrhea (CDAD), and anaphylaxis.
## Key Drug Interactions
* **Warfarin:** May increase the INR and risk of bleeding. Monitor INR closely.
* **Methotrexate:** May decrease renal clearance, increasing risk of methotrexate toxicity.
* **Probenecid:** Decreases renal tubular secretion of amoxicillin, resulting in increased blood levels.
* **Oral Contraceptives:** May decrease efficacy (though clinical evidence is inconsistent; recommend backup contraception).
## Monitoring
* Monitor for signs of anaphylaxis during the first dose.
* Periodic assessment of renal, hepatic, and hematopoietic function during prolonged therapy.
* Monitor for watery or bloody stools (r/o *C. difficile*).
## Clinical Pearls
* **Administration:** Administer at the start of a meal to minimize gastrointestinal upset and maximize absorption.
* **Formulation Warning:** Do not substitute different formulations (e.g., 250 mg vs. 500 mg tablets) due to different ratios of clavulanate; always verify the amoxicillin dosage component.
* **Clavulanate Sensitivity:** High dosages of clavulanate are strongly associated with gastrointestinal distress.
***
**Educational Disclaimer:** This information is for educational purposes only and does not constitute medical advice. Always verify current prescribing information, local antimicrobial stewardship guidelines, and patient-specific factors (e.g., allergies, renal function) before prescribing or administering medication.
